Indomethacin Extended-Release Capsules and Ivacaftor Tablets
Determining the interaction of Indomethacin Extended-Release Capsules and Ivacaftor Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor. The clinical relevance is unknown. MANAGEMENT: Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy. References "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA. "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA. "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA. "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA. View all 4 references
Professional:MONITOR: Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor. The clinical relevance is unknown.
MANAGEMENT: Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.
- "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
Generic Name: indomethacin
Brand name: Indocin, Indocin SR, Tivorbex
Synonyms: Indomethacin
Generic Name: ivacaftor
Brand name: Kalydeco
Synonyms: Ivacaftor
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Indomethacin Extended-Release Capsules-Ivermectin
- Indomethacin Extended-Release Capsules-Ivermectin (Systemic)
- Indomethacin Extended-Release Capsules-Ivermectin Cream
- Indomethacin Extended-Release Capsules-Ivermectin Lotion
- Indomethacin Extended-Release Capsules-Ivermectin Tablets
- Indomethacin Extended-Release Capsules-Ivermectin topical
- Ivacaftor Tablets-Indomethacin Injection
- Ivacaftor Tablets-Indomethacin Intravenous
- Ivacaftor Tablets-Indomethacin Rectal
- Ivacaftor Tablets-Indomethacin Suppositories
- Ivacaftor Tablets-Indomethacin Suppository
- Ivacaftor Tablets-Indomethacin Suspension